TG Therapeutics (TGTX)

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQTM (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development.

Company profile

Ticker

TGTX

Exchange

NASDAQ

Website

www.tgtherapeutics.com

CEO

Michael Weiss

Incorporated

Delaware

Location

New York

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...

Former names

ATLANTIC PHARMACEUTICALS INC, ATLANTIC TECHNOLOGY VENTURES INC, MANHATTAN PHARMACEUTICALS INC

SEC CIK

0001001316

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Ariston Pharmaceuticals, Inc. • TG Biologics, Inc. • TG Therapeutics AUS Pty Ltd ...

IRS number

363898269

TGTX stock data

1M 1Y 5Y

News

From Benzinga Pro

Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday

9 Aug 22

Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday.

Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session

8 Aug 22

Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares jumped 132% to $11.12 after jumping around 46% on Friday. The company recently said it expects unaudited comprehensive loss of $1.6 million for fiscal year ended March 31, 2022.

TG Therapeutics Q2 EPS $(0.30) Up From $(0.59) YoY

8 Aug 22

TG Therapeutics (NASDAQ:TGTX) reported quarterly losses of $(0.30) per share. This is a 49.15 percent increase over losses of $(0.59) per share from the same period last year.

12 Health Care Stocks Moving In Tuesday's After-Market Session

2 Aug 22

TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology

27 Jun 22

Press releases

From Benzinga Pro

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - TGTX

12 Aug 22

New York, New York--(Newsfile Corp. - August 12, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ:TGTX) and certain of

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of U, MOLN and TGTX

12 Aug 22

NEW YORK, NY / ACCESSWIRE / August 12, 2022 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who

TGTX CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages TG Therapeutics (TGTX) Investors with Losses to Contact Firm's Attorneys, Securities Fraud Class Action Pending

12 Aug 22

SAN FRANCISCO, CA / ACCESSWIRE / August 12, 2022 / Hagens Berman urges TG Therapeutics, Inc. (NASDAQ:TGTX) investors who suffered significant losses to submit your losses now. A securities fraud class action has been

SHAREHOLDER ALERT: TGTX YQ WEBR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

12 Aug 22

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in TG Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

12 Aug 22

Analyst ratings and price targets

Last 3 months

Average target

$11.00

Low target

$5.00

High target

$17.00

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

10 May 22

12 Aug 22

31 Dec 22

Financial summary

Financial statements Chart TGTX financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	186.94M	186.94M	186.94M	186.94M	186.94M	186.94M
Cash burn (monthly)	37.74M	23.82M	22.29M	26.87M	22.9M	23.58M
Cash used (since last report)	166.84M	105.31M	98.55M	118.79M	101.23M	104.25M
Cash remaining	20.11M	81.63M	88.39M	68.15M	85.71M	82.69M
Runway (months of cash)	0.5	3.4	4.0	2.5	3.7	3.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

TGTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	#Shares	#Remaining
20 Jul 22	Charney Laurence N	Common Stock	Grant	Acquire A	No	No	43,732	264,729
20 Jul 22	Echelard Yann	Common Stock	Grant	Acquire A	No	No	43,732	192,848
20 Jul 22	Sagar Lonial	Common Stock	Grant	Acquire A	No	No	43,732	128,732
20 Jul 22	Daniel Hume	Common Stock	Grant	Acquire A	No	No	43,732	198,239
20 Jul 22	Kenneth Hoberman	Common Stock	Grant	Acquire A	No	No	43,732	222,685

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

TGTX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	185	197	-6.1%
Opened positions	33	31	+6.5%
Closed positions	45	57	-21.1%
Increased positions	73	63	+15.9%
Reduced positions	46	62	-25.8%

13F shares	Current	Prev Q	Change
Total value	1.05B	4.04B	-74.0%
Total shares	102.63M	102.87M	-0.2%
Total puts	1.51M	1.88M	-19.7%
Total calls	2.09M	2.39M	-12.5%
Total put/call ratio	0.7	0.8	-8.2%

Largest owners	Shares	Value	Change
FMR	20.33M	$193.33M	-1.9%
Vanguard	12.13M	$115.37M	+0.3%
STT State Street	9.63M	$91.57M	+65.3%
BLK Blackrock	8.94M	$84.98M	+0.4%
Maverick Capital	6.68M	$63.51M	+10.7%
Wellington Management	4.02M	$38.24M	-5.4%
LFB Biotechnologies S.A.S.U.	2.61M	$36.48M	0.0%
683 Capital Management	2.6M	$24.72M	+115.3%
Geode Capital Management	2.19M	$20.81M	-5.3%
Millennium Management	2.18M	$20.7M	+305.8%

Largest transactions	Shares	Bought/sold	Change
Capital World Investors	0	-4.17M	EXIT
STT State Street	9.63M	+3.8M	+65.3%
Ra Capital Management	0	-2.21M	EXIT
Millennium Management	2.18M	+1.64M	+305.8%
683 Capital Management	2.6M	+1.39M	+115.3%
IVZ Invesco	330.46K	-1.32M	-80.0%
Pictet Asset Management	1.17M	-1.22M	-51.1%
Lion Point Capital	0	-1.16M	EXIT
Antara Capital	1.03M	+1.03M	NEW
Citadel Advisors	1.08M	+1.03M	+2385.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Bristol-Myers Squibb • Celgene • Astrazeneca • Roche • Viracta Therapeutics • Curis • Novartis • Oncternal Therapeutics • Stemline Therapeutics • Genmab

Management Discussion

Product revenue, net. Product revenue, net for the three months ended March 31, 2022 was $2.0 million compared to $0.8 million for the three months ended March 31, 2021. Product revenue, net consisted of net product sales of UKONIQ in the United States. In February 2021, we began commercial sales of UKONIQ within the U.S. following FDA approval. The $1.2 million increase was primarily driven by an increase in product shipments for UKONIQ as a result of greater market penetration. The increase in product shipments is partially offset by the recording of an additional allowance for sales returns in the first quarter of 2022 due to the anticipated increase in returns resulting from the voluntary withdrawal of UKONIQ from the U.S. market announced on April 15, 2022. Any product sales subsequent to the voluntary withdrawal are limited to existing patients that elect to remain on treatment and no shipments for new prescriptions are allowed. Therefore, it is expected product revenue, net will decline significantly throughout 2022 as a result of the voluntary market withdrawal of UKONIQ.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Good

New words: addtion, amplifying, anniversary, anti, ASC, Canada, canceled, Carolina, Chairman, check, convened, death, dismantle, driven, electronic, epitope, extinguishment, fashion, foreseen, France, gather, geopolitical, Georgia, Germany, glycoengineered, hoc, host, HR, imbalance, immunology, Interbank, invaded, invasion, Lender, military, NC, neighboring, North, notified, ODAC, OS, outdated, overarching, partake, path, paused, penalty, penetration, Poland, prompt, refinance, reinstated, reset, retention, retirement, Russia, Russian, Samsung, Slovakia, streamlining, SWIFT, Ukraine, undermining, unrestricted, vi, Vice, west, withdrawn, withdrew

Removed: AbbVie, acalabrutinib, account, accrue, achieved, adjustment, administer, advancing, AEs, AKS, allocated, allocating, ALT, analyst, annum, antigen, ASH, AST, AstraZeneca, ASU, authoritative, axicabtagene, Bayer, begin, bispecific, Brexit, BTK, budgetary, build, buying, calculate, calculating, capitalized, casein, channel, Checkpoint, chimeric, ciloleucel, closely, CMO, cohort, collectability, comprising, computation, Concurrently, consist, constraint, copanlisib, core, Cornell, CR, customary, damaged, delta, dependence, depict, deplete, depression, detected, display, distancing, DLBCL, drastically, duvelisib, earned, ending, enhancement, epidemic, Epizyme, epsilon, error, evolved, exacerbated, exceed, expired, explicitly, exploratory, explore, extranodal, FASB, feasible, filer, focusing, forecasted, formally, frame, Furman, generation, generically, Gilead, globe, goodwill, Gribben, hedging, heightening, hematological, Hematology, Hengrui, ibrutinib, idelalisib, immunotherapy, impairment, inclusion, inclusive, indexed, instability, integrated, interaction, interactive, intraperiod, Janssen, Japan, Jiangsu, John, language, launched, left, lenalidomide, lien, macroeconomic, MCL, Medicine, multicenter, NaN, NCCN, nodal, Novimmune, ocrelizumab, ODD, ofatumumab, opportunistic, optimal, ORR, owe, paydown, performing, persist, pharmacologic, pharmacy, phosphoinositide, prioritized, professional, promised, promote, rash, ratably, realizable, receptor, recession, recognize, recognizing, reflect, regularly, remained, remote, remotely, requesting, requirement, resume, returned, reversal, Richard, rituximab, robust, Roche, satisfied, scalable, Senate, settled, shipment, Simplifying, slowdown, specialty, splenic, spreading, Squibb, step, suitable, sum, supported, surge, targeting, tazemetostat, timeline, today, Topic, tranche, Tricare, triple, Tyrosine, underinsured, unexpectedly, uninsured, unit, variant, venetoclax, Verastem, vesting, virtual, virtually, Weill, worked, workforce, Wuhan

From filing 10-Q 2022 Q1

Financial reports

View all